Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Details for Australian Patent Application No. 2011203526 (hide)

Owner Teva Women's Health, Inc.

Inventors Diliberti, Charles E.; Reape, Kathleen Z.; Bronnenkant, Lance J.

Agent Davies Collison Cave

Pub. Number AU-A-2011203526

Parent 2005294269

Filing date 12 July 2011

Wipo publication date 4 August 2011

International Classifications

A61K 31/56 (2006.01) - Compounds containing cyclopenta[a]hydrophenanthrene ring systems

A61K 31/565 (2006.01) - not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol

A61K 31/567 (2006.01) - substituted in position 17 alpha, e.g. mestranol, norethandrolone

A61P 15/18 (2006.01) Drugs for genital or sexual disorders

Event Publications

28 July 2011 Complete Application Filed

4 August 2011 Application Open to Public Inspection

  Published as AU-A-2011203526

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011203527-Wavefield deghosting of seismic data recorded using multiple seismic sources at different water depths

2011203525-Ruggedized apparatus for analysis of nucleic acid and proteins